Combining Systemic Bisphosphonates with Palliative External Beam Radiotherapy or Bone-Targeted Radionuclide Therapy: Interactions and Effectiveness

Clinical Oncology

Volumn 21, Issue 9, 2009, Pages 665-667

  Vassiliou, V ^a   Bruland, O ^b   Janjan, N ^c   Lutz, S ^d   Kardamakis, D ^e   Hoskin, P ^f  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Blanchard Valley Regional Cancer Center   (United States)

^e UNIVERSITY OF PATRAS   (Greece)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID RE 186; PAMIDRONIC ACID; RADIOISOTOPE; SAMARIUM 153; STRONTIUM 89; ZOLEDRONIC ACID;

ADVANCED CANCER; ANALGESIA; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; HUMANS; PALLIATIVE CARE; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 70349422123     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.07.011     Document Type: Editorial

References (28)

1. Chow E., Harris K., Fan G., et al. Palliative radiotherapy trials for bone metastases. A systematic review. J Clin Oncol 25 (2007) 1423-1436
2. Vassiliou V., and Kardamakis D. The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice. Anticancer Agents Med Chem 9 (2009) 326-335
3. Hoskin P.J. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29 (2003) 321-327
4. Hoskin P.J., Ford H.T., and Harmer C.L. Hemibody irradiation (HBI) for metastatic bone pain in two histological distinct groups of patients. Clin Oncol 1 (1989) 67-69
5. Body J.J., Diel I.J., Lichinitser M.R., et al., MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
6. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
7. Mundy G.R. Metastasis to bone: causes, sequences and therapeutic opportunities. Nat Rev Cancer 2 (2002) 584-593
8. Guise T.A., and Mundy G.R. Cancer and bone. Endocr Rev 19 (1998) 18-54
9. Vassiliou V., Kalogeropoulou C., Christopoulos C., et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67 (2007) 264-272
10. Vassiliou V., Kalogeropoulou C., Giannopoulou E., et al. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24 (2007) 169-178
11. Krempien R., Huber P.E., Harms W., et al. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restoration of osteolytic bone metastases in an animal model. Cancer 98 (2003) 1318-1324
12. Arrington S.A., Damron T.A., Mann K.A., and Allen M.J. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor induced osteolysis. J Surg Oncol 97 (2008) 284-290
13. Vassiliou V., Kalogeropoulou C., Petsas T., et al. Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between the clinical status of patients and the type of bone metastases?. Clin Exp Metastasis 24 (2007) 49-56
14. Micke O., Berning D., Schäefer U., et al. Combination of ibandronate and radiotherapy in metastatic bone disease - results of a randomized study. J Clin Oncol 22 Suppl l (2003) 759
15. Kouloulias V.E., Dardoufas C.E., Kouvaris J.R., et al. Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases. Acta Oncol 41 (2002) 169-174
16. Kouloulias E.V., Kouvaris R.J., Antypas C., et al. An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther Onkol 179 (2003) 471-479
17. Kouloulias V., Matsopoulos G., Kouvaris J., et al. Radiotherapy in conjunction with intravenous infusion of 180mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessment of grey-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 57 (2003) 143-157
18. Vassiliou V, Leotsinides M, Kalogeropoulou C, et al. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer. BJU Int 2009;104:417-418.
19. Kijima T., Fujii Y., Suyama T., et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103 (2009) 620-624
20. Lewington V.J. Bone-seeking radionuclides for therapy. J Nucl Med 46 (2005) 38s-47s
21. Finlay I.G., Mason M.D., and Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6 (2005) 392-400
22. Sartor O. Radiopharmaceuticals and chemotherapy combinations in metastatic castrade-resistant prostate cancer: a new beginning. J Clin Oncol 27 (2009) 2417-2418
23. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (2009) 2429-2435
24. Morris M.J., Pandit-Taskar N., Carrasquillo J., et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27 (2009) 2436-2442
25. Lam M.G., Dahmane A., Stevens W.H., et al. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35 (2008) 756-765
26. Storto G., Klain M., Paone G., et al. Combined therapy Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39 (2006) 35-41
27. Koutsikos J., and Leondi A. Treatment efficacy of combined bisphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35 (2008) 1392-1393
28. Liang J.G., Jiang N.Y., Du J.Q., et al. Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis. Zhonghua Zhong Liu Za Zhi 27 (2005) 180-182